And Then There Were 12: Follow-on Biologics Picture Coming Into Focus
Executive Summary
It almost seems like the conference committee negotiations for follow-on biologics legislation have begun, but the two actors that the generic industry expects to best represent its issues - Rep. Henry Waxman, D-Calif., and President Obama - are not at the table